We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Shuwen Biotech and DiagnoCure Sign Exclusive License and Collaboration Agreement

News   Jun 07, 2014

 
Shuwen Biotech and DiagnoCure Sign Exclusive License and Collaboration Agreement
 
 
 

RELATED ARTICLES

Time to Say Goodbye… to the “House-hold Measure” BMI?

News

A new study published in PLOS Biology sees an international collaboration of academia and industry experts introduce a novel "revolutionary" approach towards personalized and precision biomedicine, moving away from the "classic" morphometric BMI.

READ MORE

Study Finds Commercially Available Antibodies Are Not Binding Their Target

News

In a new study, researchers have tested the binding specificity of commercial antibodies to the C9ORF72 protein, and explored a novel validation approach.

READ MORE

Personalized Immunotherapy Refined by Mass Spec-Machine Learning Pairing

News

A combination of mass spectrometry and a novel computational tool is more accurately identifying the molecular signs of cancer likely to be presented to helper T cells, which stimulate and orchestrate the immune response to tumors and infectious agents.

READ MORE

 

Like what you just read? You can find similar content on the communities below.

Cancer Research

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE